Compare Pfizer Inc (PFE) vs Sezzle Inc (SEZL) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Sezzle Inc. (SEZL) trades at $171.76, down 1.67% today, with a bullish technical signal from moving averages and a neutral RSI near 50. The stock shows strong fundamental momentum, with Q1 2026 EPS of $1.43 beating estimates of $1.24, and robust profitability metrics including a 30.83% net income margin and 91.95% ROE. Recent news highlights subscriber growth of 48.4% year-over-year and product expansions, supporting the positive sentiment.

Outlook remains favorable due to consistent earnings beats and raised guidance, but risks include high valuation multiples (P/E of 41) and competitive pressures in the BNPL sector. Analyst consensus is a Moderate Buy with a $162 price target, suggesting potential downside from current levels, though the high target of $190 indicates upside if growth persists.